首页> 外文期刊>Journal of Medicinal Chemistry >New Monocyclic, Bicyclic, and Tricyclic Ethynylcyanodienones as Activators of the Keap1/Nrf2/ARE Pathway and Inhibitors of Inducible Nitric Oxide Synthase
【24h】

New Monocyclic, Bicyclic, and Tricyclic Ethynylcyanodienones as Activators of the Keap1/Nrf2/ARE Pathway and Inhibitors of Inducible Nitric Oxide Synthase

机译:新的单环,双环和三环乙炔氰二烯酮作为Keap1 / Nrf2 / ARE途径的激活剂和诱导型一氧化氮合酶的抑制剂。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A monocyclic compound 3 (3-ethynyl-3-methyl-6-oxocyclohexa-1,4-dienecarbonitrile) is a highly reactive Michael acceptor leading to reversible adducts with nucleophiles, which displays equal or greater potency than the pentacyclic triterpenoid CDDO in inflammation and carcinogenesis related assays. Recently, reversible covalent drugs, which bind with protein targets but not permanently, have been gaining attention because of their unique features. To explore such reversible covalent drugs, we have synthesized monocyclic, bicyclic, and tricyclic compounds containing 3 as an electrophilic fragment and evaluated them as activators of the Keap1/Nrf2/ARE pathway and inhibitors of iNOS. Notably, these compounds maintain the unique features of the chemical reactivity and biological potency of 3. Among them, a monocyclic compound 5 is the most potent in these assays while a tricyclic compound 14 displays a more robust and specific activation profile compared to 5. In conclusion, we demonstrate that 3 is a useful electrophilic fragment for exploring reversible covalent drugs.
机译:单环化合物3(3-乙炔基-3-甲基-6-氧代环己-1,4-二烯甲腈)是高反应性的Michael受体,可与亲核试剂产生可逆加合物,在炎症和炎症反应中显示出与五环三萜CDDO相同或更高的效力。致癌相关分析。最近,与蛋白质靶标结合但不能永久结合的可逆共价药物因其独特的功能而受到关注。为了探索这种可逆的共价药物,我们合成了包含3作为亲电子片段的单环,双环和三环化合物,并将其评估为Keap1 / Nrf2 / ARE途径的激活剂和iNOS抑制剂。值得注意的是,这些化合物保持了3的化学反应性和生物学效能的独特特征。其中,单环化合物5在这些测定中最有效,而三环化合物14与5相比显示出更稳定,更特异性的激活特性。结论,我们证明3是用于探索可逆共价药物的有用的亲电片段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号